minimal change disease and treatment with steroids 7/24/2007 zae kim, md

28
Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Upload: harold-houston

Post on 12-Jan-2016

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Minimal change disease and treatment with steroids

7/24/2007Zae Kim, MD

Page 2: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Clinical Question

• Why does MCD respond to steroid?• Why do they develop resistance?

Page 3: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Introduction

• Most common cause of the nephrotic syndrome in children

• ~10-15% of nephrotic syndrome in adults, third most common after MN and FSGS– More common in Hispanics, Asians, Arabs and

Caucasians

• clinical and pathological entity defined by selective proteinuria and hypoalbuminemia

that occurs in the absence of– cellular glomerular infiltrates or – immunoglobulin deposits

Page 4: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Light microscopy of glomerulus in MCD

Page 5: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Immunofluorescence Microscopy

www.gamewood.net/rnet/renalpath/noimcx.jpg

Page 6: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Electron Microscopy

Page 7: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

The glomerular capillary wall

Van den Berg, Weening, Clinical Science (2004) 107, 125–136

Normal

MCD

Page 8: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

What is the Pathogenesis?

Page 9: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Pathogenesis - “Intrinsic factor”

• Genetic basis for hereditary NS• NS of the Finnish type• Autosomal-recessive steroid-resistant NS• Familial forms of FSGS• Diffuse mesangila sclerosis associated with

Denys-Drash syndrome and with Frasier syndrome

• NS associated with nail-patella syndrome

– Help elucidate molecular aspect of FSGS– Not clear for MCD

Page 10: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Molecular anatomy of the podocyte foot process

cytoskeleton

Nature Genetics  24, 333 - 335 (2000)

Page 11: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Pathogenesis – extrinsic factor, better explanation for MCD

• Clinical Observations - Shalhoub’s hypothesis– MCD frequently remits with measles infection– Corticosteroids and alkylating drugs cause a remission– Association of MCD with Hodgkin disease

• Experimental Observations– T cell hybridoma (Koyama KI 1991 (40): 453-460)– Removal of glomerular permeability factor leads to normal

kidney (Ali Transplantation 1994 Oct 15;58(7):849-52)

• “circulating factor”– possible link between T-cell response and

glomerular disease

Page 12: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

How does steroid work in MCD?

• Widely used in treatment but their mode of action is poorly understood

• What is its effectiveness in MCD where there is no evident inflammation

Page 13: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Steroid – quick overview

• Inhibitory effects on both innate and acquired immunologic function

• Innate Immune function– Reduced Inflammatory response:

• inhibit transmigration of leukocytes• attenuate the generation of inflammatory

exudates– Phospholipase A2 suppresion– COX-2 suppression

• Acquired Immune function– Antigen presenting cells, B cell and T cells

Page 14: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Overview of Intracellular Effects

Page 15: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Could steroid have more direct effect in kidney?

Page 16: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Direct effects of dexamethasone on human podocyte – Xing,

Saleem, et al• Hypothesis:

– Glucocorticoid exert direct protection of podocytes from injury and/or promotion of repair

• Nephrin: podocyte specific protein– mutation of NPHS2 gene - cause congenital nephrotic

syndrome of Finnish type– Studies show possible downregulation of nephrin in MCD

Page 17: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Result – effects of dexamethasone on podocyte maturation at 37 C and

expression of nephrin

Quantificaton of

nephrin

Immunofluorescent staining

Page 18: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Summary

• Dexamethasone enhanced and accelerated podocyte maturation, with a particulary striking effect on expression of nephrin

Page 19: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Other steroid response

In disease state

With dexamethasone

p21 Upregulated downregulation allow podocyte to enter the cell cycle – enhance ability to repair

VEGF a mitogen for vascular endotheila cells

Downregulated

p52 Induces apoptosis

downregulated

Page 20: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Overexpression of Interleukin-13 Induces Minimal-Change–Like Nephropathy in Rats

• Background– MCD may be a T cell dependent disorder that

results in glomerular podocyte dysfunction– Th2 cytokine bias in patients with MCD

• MCD associated with atopy and allergy• Relapse MCD with elevated IL-4 and IL-13

– Association between MCD and Hodgkins’s disease

• IL-13 known to be an autocrine growth factor for the Reed-Sternberg

Page 21: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Hypothesis

• IL-13 may play an important role in the development of proteinuria in MCNS by exerting a direct effect on podocytes, acting through the IL-13 receptors on the podocyte cell surface, initiating certain signaling pathways that eventually lead to changes in the expression of podocyte-related proteins (nephrin, podocin, and dystroglycan)

• IL-13 transfected mouse was used as a model

Page 22: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Mean 24-h urine albumin excretion (mg/24 h)

Page 23: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Comparison of control, IL-13-transfected mouse at experiment

end (day 70)Parameter Control Rats

(n=17)Group 1 (proteinuric rats), n=34

Grp 2: neprhrotic rats n=7

Serum albumin 42.7 +/- 1.8 40.7 +/- 1.3 25.5 +/- 2.2

Urine albumin 0.36 +/- 0.04 3.19 +/- 0.98 9.69 +/- 4.07

Serum cholesterol

1.72 +/- 0.05 2.68 +/- 0.18 6.88 +/- 1.09

Serum IL-13 7.1 +/- 1.8 241.4 +/- 69.5 708.6 +/- 257.7

Nephrin 0.16 +/- 0.03 0.11 +/- 0.01 0.01 +/- 0.005

Podocin 0.25+/- 0.05 0.17 +/- 0.02 0.01 +/- 0.005Yellow = p <0.001 vs control Red = p<0.001 vs control and Grp 1

Page 24: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Histopathologic features on day 70 at killing

(A) Glomerulus of IL-13–transfected rat showing no significant histologic changes (periodic acid-Schiff stain).

(B) Glomerulus of IL-13–transfected rat showing fusion of podocyte foot processes (arrows).

(C) Glomerulus of control rat showing normal individual podocyte foot processes along the glomerular basement membrane (GBM; arrows).

Page 25: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Immunofluorescence staining of glomeruli for protein expression of nephrin, podocin, dystroglycan, and synaptopodin

nephrin

podocin

dystroglycan

synaptopodin

Control IL-13 infected

Page 26: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

Summary

• IL-13-transfected rats– Developed minimal change like GN, as

evidence by LM and EM changes– decrease in the expression of nephrin,

podocin, and dystroglycan associated with increased urinary albumin excretion and podocyte foot process effacement

• suggesting that these proteins are essential in maintaining the filtration barrier, thus controlling

glomerular permeability• decrease was not due to loss of podocytes -

Page 27: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

What does it all mean…

• There is more to steroid than I knew…• “circulating factor”

– Prognostic indicator?

• Why are some MCDs steroid responsive while others are resistant?

Page 28: Minimal change disease and treatment with steroids 7/24/2007 Zae Kim, MD

The end